Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STEMVAC + chemotherapy
- Development stage
- Unknown
- Lead developer
- University of Washington
- Modality
- Small Molecules, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intravenous
01
Overview
STEMVAC + chemotherapy is an investigational combination therapy being evaluated for the treatment of metastatic triple-negative breast cancer (TNBC). The primary component, STEMVAC, is a multi-antigen DNA plasmid vaccine developed by the University of Washington Cancer Vaccine Institute. It is designed to encode Th1-selective epitopes from five proteins associated with cancer stem cells: endoglin (CD105), Y-box binding protein 1 (YB1), SRY-box transcription factor 2 (SOX2), cadherin 3 (CDH3), and MDM2 proto-oncogene. The vaccine aims to stimulate a Th1-mediated immune response to target and eliminate cancer stem cells, which are often resistant to standard therapies and contribute to tumor recurrence. In clinical trials, STEMVAC is administered intradermally alongside sargramostim (GM-CSF) as an adjuvant and in combination with standard-of-care chemotherapy regimens, which provide direct cytotoxic effects against the bulk tumor mass.
- Other names
- CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine + ChemotherapySTEMVAC in Metastatic Triple-Negative Breast Cancer
02
Targets
CDH3 (Cadherin-3)MDM2 (Mouse double minute 2 homolog)ENG (Integrin Beta 6)SOX2 (SRY-box transcription factor 2)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)YBX1 (Y-box-binding protein 1)
Beyond the preview
Go deeper on STEMVAC + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STEMVAC + chemotherapy.